



DOCKET NO.: 210352US0X

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

RE: Application Serial No.: 09/891,517

Applicants: Ryuichiro KURANE et al

Filing Date: June 27, 2001

For: NOVEL NUCLEIC ACID PROBES, METHOD FOR
DETERMINING CONCENTRATIONS OF NUCLEIC
ACID BY USING THE PROBES, AND METHOD
FOR ANALYZING DATA OBTAINED BY THE
METHOD

Group Art Unit: 1631

Examiner: Mary ZEMAN

SIR:

Attached hereto for filing are the following papers:

**PTO COVER LETTER
RESPONSE TO REQUIREMENT FOR RESTRICTION**

Our check in the amount of -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

T. A. Blc

Norman F. Oblon


Registration No. 24,618

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

Thomas A. Blinka, Ph.D.
Registration No. 44,541



ATTORNEYS AT LAW

NORMAN F. OBLON
(703) 413-3000
NOBLON@OBLON.COM

THOMAS A. BLINKA, PH.D.
(703) 413-8095
TBLINKA@OBLON.COM

DOCKET NO: 210352US0X



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

RYUICHIRO KURANE, ET AL.

:

: EXAMINER: ZEMAN, M.

SERIAL NO: 09/891,517

:

FILED: JUNE 27, 2001

: GROUP ART UNIT: 1631

FOR: NOVEL NUCLEIC ACID PROBES,
METHOD FOR DETERMINING
CONCENTRATIONS OF NUCLEIC ACID
BY USING THE PROBES, AND METHOD
FOR ANALYZING DATA OBTAINED BY
THE METHOD

RESPONSE TO REQUIREMENT FOR RESTRICTION

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Official Action of September 9, 2003, Applicants elect, with
traverse, Group IX, Claims 23-28, and 42, drawn to a fifth method, PCR-based.

Remarks begin on page 2 of this paper.